Raras
Buscar doenças, sintomas, genes...
Deficiência materna de riboflavina
ORPHA:411712CID-10 · P00.4DOENÇA RARA

A cobalamina, também conhecida como vitamina B12, é uma vitamina hidrossolúvel envolvida no metabolismo. Possui as seguintes características:Necessária à eritropoiese, e em parte do metabolismo dos aminoácidos e dos ácidos nucleicos; Previne problemas cardíacos e derrame cerebral; Necessária para uma boa manutenção do sistema nervoso.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Deficiência materna de riboflavina é uma doença rara autossômica dominante causada por mutações no gene SLC52A1. Caracteriza-se por deficiência de riboflavina na mãe, podendo levar a complicações na gestação e no desenvolvimento fetal.

Publicações científicas
10 artigos
Último publicado: 2026 Jan

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
<1 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Casos conhecidos
2
pacientes catalogados
Início
Adult
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: P00.4
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico10PubMed
Últimos 10 anos4publicações
Pico20191 papers
Linha do tempo
2026Hoje · 2026
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal dominant.

SLC52A1Solute carrier family 52, riboflavin transporter, member 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Plasma membrane transporter mediating the uptake by cells of the water soluble vitamin B2/riboflavin that plays a key role in biochemical oxidation-reduction reactions of the carbohydrate, lipid, and amino acid metabolism (PubMed:18632736, PubMed:20463145). Humans are unable to synthesize vitamin B2/riboflavin and must obtain it via intestinal absorption (PubMed:20463145) (Microbial infection) May function as a cell receptor to retroviral envelopes similar to the porcine endogenous retrovirus (P

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
Vitamin B2 (riboflavin) metabolism
MECANISMO DE DOENÇA

Riboflavin deficiency

A disorder caused by a primary defect in riboflavin metabolism, or by dietary riboflavin deficiency. Riboflavin deficiency during pregnancy results in hypoglycemia, metabolic acidosis, dicarboxylic aciduria and elevated plasma acylcarnitine levels in the newborn. Treatment with oral riboflavin results in complete resolution of the clinical and biochemical findings.

EXPRESSÃO TECIDUAL(Tecido-específico)
Skin Sun Exposed Lower leg
6.2 TPM
Intestino delgado
5.0 TPM
Skin Not Sun Exposed Suprapubic
4.7 TPM
Próstata
1.6 TPM
Esôfago - Mucosa
1.3 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
ariboflavinosismaternal riboflavin deficiency
HGNC:30225UniProt:Q9NWF4

Variantes genéticas (ClinVar)

44 variantes patogênicas registradas no ClinVar.

🧬 SLC52A1: NM_017986.4(SLC52A1):c.324G>C (p.Gln108His) ()
🧬 SLC52A1: NM_017986.4(SLC52A1):c.1134+5G>A ()
🧬 SLC52A1: GRCh37/hg19 17p13.2(chr17:4354194-5387525)x1 ()
🧬 SLC52A1: GRCh37/hg19 17p13.2-12(chr17:4678235-14745263)x3 ()
🧬 SLC52A1: GRCh37/hg19 17p13.3-11.2(chr17:525-21510992)x3 ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 3 variantes classificadas pelo ClinVar.

2
1
Patogênica (66.7%)
VUS (33.3%)
VARIANTES MAIS SIGNIFICATIVAS
SLC52A1: NM_017986.4(SLC52A1):c.844CTG[3] (p.Leu283_Gly284insLeu) [Conflicting classifications of pathogenicity]
SLC52A1: Single allele [Pathogenic]
SLC52A1: NM_017986.4(SLC52A1):c.546del (p.Pro183fs) [Uncertain significance]

Vias biológicas (Reactome)

1 via biológica associada aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Deficiência materna de riboflavina

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
4 papers (10 anos)
#1

Impact of Maternal Riboflavin Deficiency on the Growth and Development of Offspring Rats.

Birth defects research2026 Jan

Riboflavin (vitamin B2) is crucial for energy metabolism and several physiological processes. Pregnant women have a greater chance of being riboflavin-deficient, but its effects on offspring development remain understudied. Two-month-old female Wistar (WNIN) rats were randomly divided into three groups: control (AIN-93G diet with 5 mg/kg riboflavin), pair-fed, and riboflavin-deficient (0.5 mg/kg). After 6 weeks, riboflavin deficiency was confirmed in the riboflavin-deficient group. All groups of rats were allowed to mate with male littermates. The pups stayed with their mothers during lactation and received a diet similar to the mothers' during weaning. Four pup groups were studied: control, pair-fed, deficient, and replenished. Blood FAD levels were estimated using HPLC. Reproductive indices in dams, developmental milestones, and morphometric data in pups were assessed. Pups were maintained for 6 weeks (postnatal day 42) before being sacrificed. Adult female rats fed a riboflavin-deficient diet showed decreased body weight. While maternal fertility and pregnancy indices were unaffected, litter size was reduced in the riboflavin-deficient group of dams. Pups born to deficient dams exhibited delayed milestones, including pinna unfolding, eye slit formation, and fur coat formation. Morphometric measures, such as body weight, body length, and abdominal circumference, were significantly lower. Post-weaning mortality was higher in the deficient group, likely due to hypoglycemia. Replenishment with a riboflavin-sufficient diet partially improved the outcomes. Maternal riboflavin deficiency impairs offspring growth and developmental milestones. Adequate maternal riboflavin intake is critical for ensuring optimal fetal and postnatal development.

#2

Maternal riboflavin deficiency causes embryonic defects by activating ER stress-induced hepatocyte apoptosis pathway.

Free radical biology &amp; medicine2024 Nov 01

Riboflavin deficiency (RD) induces liver damage, abnormal embryonic development, and high mortality. We hypothesized that the phenotype could be rescued by inhibiting ER stress. The objectives of the present study were to investigate the underlying molecular mechanisms of RD-induced embryonic defects using in vitro and in vivo models. Primary duck embryonic hepatocytes were treated with an ER stress inhibitor (4-PBA) or transfected with CHOP siRNA, and cultured in RD medium and riboflavin-sufficient (CON) medium for 8 days. Laying ducks (n = 20 cages/diet, 1 bird/cage) were fed an RD diet or CON diet for 14 wk, and the eggs were collected for hatching. At day 7 of incubation, the fertilized RD eggs were injected with or without 4-PBA into the yolk. RD decreased cell number and cell viability compared to the CON group, induced oxidative stress and apoptosis in primary duck embryonic hepatocytes. However, after being treated with an ER stress inhibitor (4-PBA) or transfected with CHOP siRNA, the apoptosis rate in RD hepatocytes decreased by 60.6 % and 86.1 %, respectively, being equal to the CON. These results indicated that RD-induced hepatocyte apoptosis is mediated by ER stress and the CHOP pathway. In vivo, RD embryos showed low hatchability, abnormal development, liver damage, ER stress, and apoptosis compared to the CON group. However, 4-PBA administration, as a model of ER stress inhibition, substantially restored embryonic development and alleviated liver damage in the RD group, including ER stress and apoptosis. Notably, hatchability in the RD group increased from 21.7 % to 72.7 % after 4-PBA treatment, though it remained less than the CON group (87.7 %). These results implicated ER stress-CHOP-apoptosis pathway as molecular mechanisms underlying RD-induced abnormal embryonic development and death, this target with potential for therapy or intervention.

#3

Abnormal VLCADD newborn screening resembling MADD in four neonates with decreased riboflavin levels and VLCAD activity.

JIMD reports2021 Sep

Early detection of congenital disorders by newborn screening (NBS) programs is essential to prevent or limit disease manifestation in affected neonates. These programs balance between the detection of the highest number of true cases and the lowest number of false-positives. In this case report, we describe four unrelated cases with a false-positive NBS result for very-long-chain acyl-CoA dehydrogenase deficiency (VLCADD). Three neonates presented with decreased but not deficient VLCAD enzyme activity and two of them carried a single heterozygous ACADVL c.1844G>A mutation. Initial biochemical investigations after positive NBS referral in these infants revealed acylcarnitine and organic acid profiles resembling those seen in multiple acyl-CoA dehydrogenase deficiency (MADD). Genetic analysis did not reveal any pathogenic mutations in the genes encoding the electron transfer flavoprotein (ETF alpha and beta subunits) nor in ETF dehydrogenase. Subsequent further diagnostics revealed decreased levels of riboflavin in the newborns and oral riboflavin administration normalized the MADD-like biochemical profiles. During pregnancy, the mothers followed a vegan, vegetarian or lactose-free diet which probably caused alimentary riboflavin deficiency in the neonates. This report demonstrates that a secondary (alimentary) maternal riboflavin deficiency in combination with reduced VLCAD activity in the newborns can result in an abnormal VLCADD/MADD acylcarnitine profile and can cause false-positive NBS. We hypothesize that maternal riboflavin deficiency contributed to the false-positive VLCADD neonatal screening results.

#4

Maternal diet deficient in riboflavin induces embryonic death associated with alterations in the hepatic proteome of duck embryos.

Nutrition &amp; metabolism2019

Maternal riboflavin deficiency (RD) induces embryonic death in poultry. The underlying mechanisms, however, remain to be established and an overview of molecular alterations at the protein level is still lacking. We investigated embryonic hepatic proteome changes induced by maternal RD to explain embryonic death. A total of 80 45-week-old breeding female ducks were divided into two groups of 40 birds each, and all birds were raised individually for 8 weeks. All the female ducks received either a RD or a riboflavin adequate (control, CON) diet, which supplemented the basal diet with 0 or 10 mg riboflavin /kg of diet respectively. The riboflavin concentrations of maternal plasma and egg yolk, as well as egg hatchability declined markedly in the RD group compared to those in the CON group after 2 weeks, and declined further over time. The hepatic proteome of E13 viable embryos from 8-week fertile eggs showed that 223 proteins were upregulated and 366 proteins were downregulated (> 1.5-fold change) in the RD group compared to those in the CON group. Pathway analysis showed that differentially expressed proteins were mainly enriched in the fatty acid beta-oxidation, electron transport chain (ETC), and tricarboxylic acid (TCA) cycle. Specifically, all the proteins involved in the fatty acid beta-oxidation and ETC, as well as six out of seven proteins involved in the TCA cycle, were diminished in the RD group, indicating that these processes could be impaired by RD. Maternal RD leads to embryonic death of offspring and is associated with impaired energy generation processes, indicated by a number of downregulated proteins involved in the fatty acid beta-oxidation, ETC, and TCA cycle in the hepatic of duck embryos. These findings contribute to our understanding of the mechanisms of liver metabolic disorders due to maternal RD.

Publicações recentes

Ver todas no PubMed

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Deficiência materna de riboflavina.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Deficiência materna de riboflavina

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ainda não achamos doenças com sintomas parecidos o suficiente.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Impact of Maternal Riboflavin Deficiency on the Growth and Development of Offspring Rats.
    Birth defects research· 2026· PMID 41492718mais citado
  2. Maternal riboflavin deficiency causes embryonic defects by activating ER stress-induced hepatocyte apoptosis pathway.
    Free radical biology &amp; medicine· 2024· PMID 39241988mais citado
  3. Abnormal VLCADD newborn screening resembling MADD in four neonates with decreased riboflavin levels and VLCAD activity.
    JIMD reports· 2021· PMID 34485012mais citado
  4. Maternal diet deficient in riboflavin induces embryonic death associated with alterations in the hepatic proteome of duck embryos.
    Nutrition &amp; metabolism· 2019· PMID 30918526mais citado
  5. Maternal riboflavin deficiency, resulting in transient neonatal-onset glutaric aciduria Type 2, is caused by a microdeletion in the riboflavin transporter gene GPR172B.
    Hum Mutat· 2011· PMID 21089064recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:411712(Orphanet)
  2. MONDO:0014013(MONDO)
  3. GARD:17686(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Artigo Wikipedia(Wikipedia)
  7. Q4138764(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Deficiência materna de riboflavina
Compêndio · Raras BR

Deficiência materna de riboflavina

ORPHA:411712 · MONDO:0014013
Prevalência
<1 / 1 000 000
Casos
2 casos conhecidos
Herança
Autosomal dominant
CID-10
P00.4 · Feto e recém-nascido afetados por transtornos nutricionais maternos
Início
Adult
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0035528
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades